Featured Research

from universities, journals, and other organizations

New AIDS Vaccine Approach Aims to Catch Virus in the Act

Date:
January 20, 1999
Source:
Howard Hughes Medical Institute
Summary:
A novel approach to producing antibodies against the AIDS virus has proven effective against a wide range of HIV strains, raising the hope that a broadly effective vaccine is possible. The new approach generates immune system antibodies against the infective proteins of the virus while the virus is fusing with a target cell.

January 15, 1999 — A novel approach to producing antibodies against the AIDS virus has proven effective against a wide range of HIV strains, raising the hope that a broadly effective vaccine is possible. The new approach generates immune system antibodies against the infective proteins of the virus while the virus is fusing with a target cell.

Scientists from the University of Montana and the Howard Hughes Medical Institute (HHMI) at New York University Medical Center sought to "freeze" the AIDS viral machinery in the act of contorting itself to fuse with its target cell. The investigators believed that this transition stage in the infective process exposes immune-triggering molecules that the virus normally keeps hidden within the depths of its structure.

The scientists' success at producing broadly effective antibodies against HIV is in sharp contrast to previous efforts, in which the resulting antibodies neutralized laboratory-grown HIV strains, but not "primary isolates," strains of the virus found in AIDS patients.

Reporting the new findings in the January 15, 1999, issue of the journal Science are University of Montana researchers Jack Nunberg, Rachel LaCasse, Kathryn Follis and Meg Trahey; and Dan Littman and John Scarborough of HHMI at New York University Medical Center.

"Perhaps to the surprise of all involved, this ambitious experiment worked," wrote AIDS researchers David Montefiori and John Moore in a commentary on this work that was also published in the January 15 issue of Science. "The mouse sera, and antibodies purified from them, inhibited the infectivity of an impressive array of diverse HIV-1 primary isolates, including viruses from multiple genetic subtypes." Montefiori is at Duke University Medical Center, and Moore is at The Rockefeller University.

Nunberg and his colleagues began by constructing a molecular facsimile of the AIDS infective machinery and of the receptors to which it binds on surface of host cells.

They first genetically engineered monkey cells to produce the HIV surface, or envelope, molecules that are responsible for grabbing onto human cells in the infective process. These surface molecules are called glycoproteins. The researchers then mixed these monkey cells with human cells whose surface was festooned with the receptors that HIV latches onto in infecting cells.

The scientists "froze" the combined cells in the act of fusing by treating them with a weak solution of formaldehyde, which forged a web of chemical links that trapped the molecules in place.

The researchers then injected this mixture, which they dubbed a "fusion-competent immunogen," into mice that Littman's team had genetically engineered to also produce the human receptors. Littman's group had developed the mice specifically to serve as models for HIV vaccine development. Using such mice for immunization was necessary to avoid having the animals' immune system react to the foreign human receptors, rather than to the HIV machinery.

Finally, the Montana scientists isolated an antibody-rich blood serum from the immunized mice. They tested this serum's effectiveness against HIV by mixing it with a diverse collection of viruses isolated from infected humans. The researchers discovered that the antibodies effectively neutralized every one of the many different strains of HIV.

"I think it's a very, very encouraging development," says Littman. "Until now, it has been very difficult to generate antibodies against HIV envelope glycoprotein that are broadly reactive. This is really the first example of being able to somehow trick the immune system into making broadly neutralizing antibodies that are presumably active against the HIV envelope glycoprotein."

Nunberg, Littman and their colleagues emphasize that while the new approach is highly promising, much work remains for the method to prove useful in a vaccine for humans. For one thing, they said, injection of whole live cells into humans is not practical in terms of vaccine safety or durability.

Rather, said Littman, a vaccine will likely depend on isolating the specific glycoprotein that triggers response to HIV and producing it using recombinant DNA technology. "Based on this advance, however, I think there is a good possibility that we'll be able to mimic the immunogenic properties of fusion-competent envelopes on cells by instead using recombinant proteins," he said.

The scientists also said it will be important to determine whether the antibodies they generated in mice can also be generated in primates and, eventually, in humans.


Story Source:

The above story is based on materials provided by Howard Hughes Medical Institute. Note: Materials may be edited for content and length.


Cite This Page:

Howard Hughes Medical Institute. "New AIDS Vaccine Approach Aims to Catch Virus in the Act." ScienceDaily. ScienceDaily, 20 January 1999. <www.sciencedaily.com/releases/1999/01/990120075328.htm>.
Howard Hughes Medical Institute. (1999, January 20). New AIDS Vaccine Approach Aims to Catch Virus in the Act. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/1999/01/990120075328.htm
Howard Hughes Medical Institute. "New AIDS Vaccine Approach Aims to Catch Virus in the Act." ScienceDaily. www.sciencedaily.com/releases/1999/01/990120075328.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Thousands Who Can't Afford Medical Care Flock to Free US Clinic

Thousands Who Can't Afford Medical Care Flock to Free US Clinic

AFP (July 23, 2014) America may be the world’s richest country, but in terms of healthcare, the World Health Organisation ranks it 37th. Thousands turned out for a free clinic run by "Remote Area Medical" with a visit from the Governor of Virginia. Duration: 2:40 Video provided by AFP
Powered by NewsLook.com
Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins